Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Molecular Therapy Year : 2014

Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients

Marie Montus
  • Function : Author
Claire Wary
  • Function : Author
Amélie Moraux
  • Function : Author
  • PersonId : 938910
Virginie Latournerie
  • Function : Author
Philippe Veron
  • Function : Author
Sylvie Boutin
  • Function : Author
Christian Leborgne
Diana Desgue
  • Function : Author
Nicolas Laroudie
  • Function : Author
Christel Rivière
  • Function : Author
Stéphanie Bucher
  • Function : Author
Thanh-Hoa Le
  • Function : Author
Nicolas Delaunay
  • Function : Author
  • PersonId : 860376
Mehdi Gasmi
  • Function : Author
Carole Masurier
  • Function : Author
  • PersonId : 858686
Jean-Yves Hogrel
  • Function : Author
  • PersonId : 901910

Abstract

Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disorder caused by mutations in the dystrophin gene, without curative treatment yet available. Our study provides, for the first time, the overall safety profile and therapeutic dose of a recombinant adeno-associated virus vector, serotype 8 (rAAV8) carrying a modified U7snRNA sequence promoting exon skipping to restore a functional in-frame dystrophin transcript, and injected by locoregional transvenous perfusion of the forelimb. Eighteen Golden Retriever Muscular Dystrophy (GRMD) dogs were exposed to increasing doses of GMP-manufactured vector. Treatment was well tolerated in all, and no acute nor delayed adverse effect, including systemic and immune toxicity was detected. There was a dose relationship for the amount of exon skipping with up to 80% of myofibers expressing dystrophin at the highest dose. Similarly, histological, nuclear magnetic resonance pathological indices and strength improvement responded in a dose-dependent manner. The systematic comparison of effects using different independent methods, allowed to define a minimum threshold of dystrophin expressing fibers (>33% for structural measures and >40% for strength) under which there was no clear-cut therapeutic effect. Altogether, these results support the concept of a phase 1/2 trial of locoregional delivery into upper limbs of nonambulatory DMD patients.

Dates and versions

inserm-02447482 , version 1 (21-01-2020)

Identifiers

Cite

Caroline Le Guiner, Marie Montus, Laurent Servais, Yan Cherel, Virginie François, et al.. Forelimb Treatment in a Large Cohort of Dystrophic Dogs Supports Delivery of a Recombinant AAV for Exon Skipping in Duchenne Patients. Molecular Therapy, 2014, 22 (11), pp.1923-1935. ⟨10.1038/mt.2014.151⟩. ⟨inserm-02447482⟩
79 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More